Published in Oncology Business Week, May 16th, 2004
FK228 (depsipeptide) is currently in phase II clinical trials for the treatment of renal cell carcinoma and hormone refractory prostate cancer. FK228 is also being studied in separate phase II clinical trials for the treatment of cutaneous T-cell lymphoma, as well as other indications by the National...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.